CMPS [NASD]
COMPASS Pathways plc
Index- P/E- EPS (ttm)-1.99 Insider Own20.20% Shs Outstand42.48M Perf Week-8.91%
Market Cap718.28M Forward P/E- EPS next Y-2.76 Insider Trans-0.40% Shs Float17.29M Perf Month47.97%
Income-83.70M PEG- EPS next Q-0.65 Inst Own17.90% Short Float20.10% Perf Quarter134.47%
Sales- P/S- EPS this Y-6.80% Inst Trans-7.75% Short Ratio9.90 Perf Half Y19.27%
Book/sh5.29 P/B3.38 EPS next Y-14.50% ROA-29.70% Target Price65.11 Perf Year-40.88%
Cash/sh5.16 P/C3.47 EPS next 5Y- ROE-31.20% 52W Range6.54 - 49.51 Perf YTD-19.05%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-63.87% Beta-
Dividend %- Quick Ratio17.50 Sales past 5Y- Gross Margin- 52W Low173.55% ATR1.56
Employees116 Current Ratio17.50 Sales Q/Q- Oper. Margin- RSI (14)59.27 Volatility9.02% 9.57%
OptionableYes Debt/Eq0.00 EPS Q/Q-12.50% Profit Margin- Rel Volume0.94 Prev Close18.35
ShortableYes LT Debt/Eq0.00 EarningsAug 04 BMO Payout- Avg Volume351.04K Price17.89
Recom1.60 SMA209.43% SMA5038.73% SMA2003.96% Volume328,572 Change-2.53%
Oct-29-21Initiated Oppenheimer Outperform $50
Jul-13-21Initiated Citigroup Buy $67
Jun-28-21Initiated Maxim Group Buy $70
May-11-21Initiated Cantor Fitzgerald Overweight $71
Apr-01-21Initiated ROTH Capital Buy $88
Oct-14-20Initiated H.C. Wainwright Buy $65
Oct-13-20Initiated Evercore ISI Outperform
Oct-13-20Initiated Cowen Outperform
Oct-13-20Initiated Canaccord Genuity Buy $80
Oct-13-20Initiated Berenberg Buy $50
Aug-09-22 09:43PM  
Aug-08-22 09:55AM  
Aug-04-22 07:30PM  
07:00AM  
Aug-02-22 04:05PM  
Aug-01-22 08:00AM  
Jul-28-22 04:00AM  
Jul-26-22 08:00AM  
Jul-19-22 08:00AM  
Jun-03-22 09:55AM  
May-23-22 07:00AM  
May-22-22 09:26AM  
May-12-22 08:00AM  
May-10-22 12:30PM  
07:00AM  
May-09-22 07:00AM  
07:00AM  
May-03-22 08:00AM  
07:00AM  
Apr-20-22 07:00AM  
Apr-19-22 08:07AM  
Apr-12-22 12:44PM  
Apr-04-22 08:00AM  
Mar-24-22 05:00AM  
Mar-02-22 07:00AM  
Feb-24-22 07:30PM  
07:12AM  
Feb-17-22 12:21PM  
07:00AM  
Jan-19-22 07:00AM  
Jan-10-22 07:00AM  
Jan-04-22 07:00AM  
Dec-23-21 06:48AM  
Dec-22-21 01:43PM  
Dec-17-21 07:00AM  
Dec-16-21 07:40AM  
Dec-13-21 07:00AM  
05:21AM  
Dec-08-21 06:48PM  
Dec-06-21 07:01AM  
Dec-03-21 07:00AM  
Dec-01-21 07:00AM  
Nov-30-21 08:00AM  
Nov-29-21 07:00AM  
Nov-28-21 07:17AM  
Nov-23-21 07:00AM  
Nov-21-21 06:45AM  
Nov-18-21 01:25PM  
Nov-13-21 06:11AM  
Nov-12-21 08:17AM  
Nov-11-21 10:00AM  
Nov-09-21 09:31PM  
04:20PM  
03:48PM  
10:38AM  
08:52AM  
07:18AM  
07:00AM  
Nov-08-21 10:52AM  
07:00AM  
Nov-03-21 08:00AM  
Nov-02-21 08:22AM  
Oct-26-21 01:49PM  
06:50AM  
Oct-22-21 06:55AM  
Oct-20-21 09:00AM  
08:34AM  
Oct-19-21 07:00AM  
Oct-17-21 07:30PM  
Oct-15-21 11:42AM  
Oct-05-21 06:29PM  
Sep-29-21 06:12AM  
Sep-24-21 08:03AM  
Sep-21-21 08:00AM  
Sep-20-21 12:51PM  
08:57AM  
Sep-14-21 07:30AM  
07:00AM  
Sep-10-21 07:00AM  
Sep-07-21 10:00AM  
07:03AM  
Sep-03-21 08:19AM  
06:47AM  
Aug-31-21 10:33AM  
Aug-26-21 07:39AM  
Aug-18-21 08:03AM  
Aug-14-21 09:34AM  
Aug-11-21 10:30PM  
07:00AM  
Aug-04-21 12:07PM  
08:27AM  
Aug-03-21 08:00AM  
Jul-29-21 03:57PM  
02:10PM  
08:30AM  
Jul-20-21 06:12AM  
Jul-14-21 12:57PM  
Jul-09-21 08:24AM  
Jul-07-21 07:00AM  
Jul-06-21 04:47PM  
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Malievskaia EkaterinaChief Innovation OfficerMar 29Sale12.486,37279,5234,284,201Mar 31 02:38 PM
Malievskaia EkaterinaChief Innovation OfficerMar 29Sale12.486,37279,5234,268,197Mar 31 02:38 PM
Goldsmith George JayChief Executive OfficerMar 29Sale12.486,37279,5234,268,197Mar 31 02:24 PM
Goldsmith George JayChief Executive OfficerMar 29Sale12.486,37279,5234,284,201Mar 31 02:24 PM
Norton David YDirectorMar 29Sale12.483,38442,23220,356Mar 31 02:12 PM
Jenkins AnnalisaDirectorMar 29Sale12.483,38442,23220,356Mar 31 02:09 PM